top of page
News
May 2026
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
September 2025
Dr. Andrea Chicca, CEO, shares the highly promising results from Synendos Phase 1 Trials
September 2025
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials
July 2025
Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy
March 2025
Synendos has been selected as a finalist of the Swiss Economic Award 2025
bottom of page